The results of the second phase demonstrated a 95% success rate in single cell isolation and library construction. Single cell RNA-seq showed distinct clusters of cells at various differentiation stages. The high reproducibility of results within sample groups will support development of novel cell therapies and validate production processes.
“Namocell’s single cell isolation platforms and Takara Bio’s single cell analysis products enabled us to take a deep look at the biology underlying our cell therapy platform and make key advances in development. Namocell’s gentle cell dispensing technology enabled us to obtain reliable and consistent phenotype information on our cells. Takara Bio’s reagents and sequencing technology yielded extremely consistent sample quality and very high information content. The results from this collaboration will be valuable for our development programs,” said Dr. Eric Schuur, CEO of HepaTx.
“We are excited to see the second phase results, and glad that our Single Cell Dispensers ...
